Compounded Semaglutide Explained
HelloNation has published an article explaining the advantages of compounded semaglutide for weight loss, as an alternative to branded GLP-1 drugs. The piece, featuring pharmacist Corey Dolan, examines how personalized compounding, particularly in sublingual form, is being used in modern weight management.
- The U.S. Food and Drug Administration (FDA) does not review compounded drugs for safety, quality, or effectiveness in the same way it reviews approved medications. The agency has issued specific warnings about compounded semaglutide, citing reports of adverse events and the use of unapproved ingredients. - A key concern is that some compounding pharmacies use salt-based forms, like semaglutide sodium and semaglutide acetate, instead of the pure base ingredient found in drugs like Ozempic and Wegovy. The FDA has stated these salt forms are different active ingredients whose safety and efficacy have not been established. - The FDA declared an end to the semaglutide drug shortage in February 2025, which had previously allowed for broader compounding to meet patient demand. Consequently, the agency set deadlines of April 22, 2025, and May 22, 2025, for different types of pharmacies to cease distributing compounded "copies" of the medication. - The agency has received hundreds of adverse event reports related to compounded semaglutide, with some cases requiring hospitalization. Many errors stem from patients receiving medication in multi-dose vials instead of the pre-filled pens used for branded versions, leading to confusion and significant overdoses. - In response to the proliferation of these unapproved drugs, Novo Nordisk, the manufacturer of Ozempic and Wegovy, has filed multiple lawsuits against medical spas, weight loss clinics, and pharmacies for patent infringement and the unlawful sale of compounded semaglutide. - Despite the end of the official shortage, prescription volume for compounded GLP-1s has continued to increase. Some compounding pharmacies now add extra ingredients, such as B vitamins, which may be an attempt to create a distinct product to navigate the updated regulatory landscape. - The global market for semaglutide is projected to grow significantly, with one analysis estimating it could reach over $47 billion by 2032, up from around $25 billion in 2025. The high cost and demand for branded versions helped create a billion-dollar market for the less-regulated compounded alternatives.
